Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Haihe Biopharma Co., Ltd. clinical trials
Also known as 海和药物.
The registry lists 20 studies whose lead sponsor is Haihe Biopharma Co., Ltd.. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 17, 2026.
Keep track of what changes. Save the Haihe Biopharma Co., Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Haihe Biopharma Co., Ltd..
- Haihe Biopharma Co., Ltd.20 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 20 of 20.
- Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)RecruitingNCT06975618Phase 1/2
- Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell LymphomaRecruitingNCT06909877Phase 1/2
- Evaluate the Safety and Clinical Activity of HH2853RecruitingNCT04390737Phase 1/2
- Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung CancerRecruitingNCT04270591Phase 1/2
- Lucitanib (AL3810) in Patients With Advanced Thymic Carcinoma After ChemotherapyCompletedNCT07824505Phase 2
- A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell CarcinomaActive, not recruitingNCT05043922Phase 2
- Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33CompletedNCT03544905Phase 1
- A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid TumorsCompletedNCT03457532Phase 1
- Study to Evaluate the Safety and Anti-tumor Activity of SCC244CompletedNCT03466268Phase 1
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced TumorsTerminatedNCT04198818Phase 1/2
- Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.TerminatedNCT04586335Phase 1
- First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid TumorsTerminatedNCT04746612Phase 1
- Single Dose Glumetinib in Healthy Chinese Male SubjectsCompletedNCT05507294Phase 1
- Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast CancerStatus unknownNCT04856371Phase 1
- Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR InhibitorsStatus unknownNCT04338243Phase 1/2
- This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in PatientsStatus unknownNCT04254471Phase 2/3
- Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810Status unknownNCT03260179Phase 1
- Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid TumorsStatus unknownNCT02870036Phase 1
- Study of the AL3810 in the Treatment of Advanced Solid TumorCompletedNCT03117101Phase 1
- Study of Simmitecan Hydrochloride in the Treatment of Advanced Solid TumorCompletedNCT01832298Phase 1